On May 22, 2025 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco") and Instil Bio, Inc. (Nasdaq: TIL, "Instil") , reported clinical trial updates of IMM2510/AXN-2510 and NSCLC clinical development strategy (Press release, ImmuneOnco Biopharma, MAY 22, 2025, View Source [SID1234655710]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Wenzhi Tian, CEO of ImmuneOnco said: "Our collaboration on IMM2510/AXN-2510 has achieved meaningful progress. We are actively conducting a Phase 2 clinical trial of IMM2510/AXN-2510 in combination with chemotherapy in patients with first-line NSCLC. The data generated to date underscore its best-in-class potential within the promising PD-(L)1xVEGF class. We anticipate sharing further clinical data in the second half of 2025."
Bronson Crouch, CEO of Instil said: "We are delighted with the significant clinical advancements by our collaborator, ImmuneOnco, with IMM2510/AXN-2510 for NSCLC in China. We are confident that IMM2510/AXN-2510 has the potential to emerge as a leading PD-(L)1xVEGF bispecific antibody, and we look forward to the initial results from the ongoing first-line chemotherapy combination trial in China. In parallel, we are advancing preparations to initiate U.S. clinical development later this year, and we look forward to bringing this potential important new medicine to patients globally."
Phase 2 Trial of IMM2510/AXN-2510 in Combination with Chemotherapy in Front-Line NSCLC
●ImmuneOnco expects to complete enrollment of approximately 60 patients in Q3 2025 in its Phase 2 trial of IMM2510/AXN-2510 in combination with chemotherapy in patients with NSCLC in the first-line setting in China.
● Among more than 30 NSCLC patients enrolled(including the safety run-in), more than 20 first-line NSCLC patients have been treated since the end of March.
●ImmuneOnco anticipates sharing initial safety and efficacy results from this Phase 2 trial in the second half of 2025.
IMM2510/AXN-2510 Monotherapy Data in Relapsed/Refractory NSCLC (China)
●The objective response rate(ORR)is similar to datasets from competitor PD-(L)1xVEGF bispecific antibodies at a similar stage of development in patients with previously treated NSCLC, showing ORR of 23%(efficacy evaluable n=13).
●The updated clinical safety from the full IMM2510/AXN-2510 monotherapy trial(n=106)and efficacy data in NSCLC are further detailed in a new corporate deck posted on ImmuneOnco’s investor relations webpage at :